State Street Corp Corbus Pharmaceuticals Holdings, Inc. Transaction History

State Street Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.12 - $8.83 $47,461 - $3.49 Million	-395,513 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$0.32 - $0.67 $12,257 - $25,663	38,304 Added 10.72%	395,513 $210,000
Q3 2021 Nov 15, 2021	BUY	$1.01 - $1.82 $4,545 - $8,190	4,500 Added 1.28%	357,209 $364,000
Q2 2021 Aug 16, 2021	SELL	$1.39 - $2.21 $1.66 Million - $2.65 Million	-1,197,106 Reduced 77.24%	352,709 $645,000
Q1 2021 May 17, 2021	BUY	$1.27 - $3.42 $274,661 - $739,639	216,269 Added 16.22%	1,549,815 $3.05 Million
Q4 2020 Feb 16, 2021	SELL	$0.94 - $1.89 $14.4 Million - $28.9 Million	-15,284,603 Reduced 91.98%	1,333,546 $1.67 Million
Q3 2020 Nov 10, 2020	BUY	$1.5 - $9.38 $20.4 Million - $127 Million	13,572,065 Added 445.56%	16,618,149 $29.9 Million
Q2 2020 Aug 14, 2020	BUY	$4.79 - $8.39 $9.05 Million - $15.9 Million	1,889,460 Added 163.36%	3,046,084 $25.6 Million
Q1 2020 May 11, 2020	BUY	$3.44 - $7.21 $3.98 Million - $8.34 Million	1,156,624 New	1,156,624 $6.06 Million

38.7K

Ticker CRBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,268,000
Market Cap $2.08B
Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.